Elucid, a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today an

Growth-focused leader will help bring the company’s AI-powered cardiovascular technology to marketBOSTON--(BUSINESS WIRE)-- Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Andrew Miller as its chief technology officer (CTO). In this role, Andrew will lead the technological strategy and oversee the engineering team’s execution. Elucid’s software is the only FDA-cleared non-invasive tool able to accurately characterize arterial plaque, simulating what pathologists would see under a microscope and establishing a histologic ground truth. Elucid is also pursuing an indication for FFRCT, uniquely derived from its PlaqueIQ technology, to non-invasively measure coronary blockages and the extent of ischemia.“We’re thrilled to welcome Andrew as CTO. He has an incredible technological skillset and proven track record in building high-performing technology teams across numerous successful organizations throughout his career,” said Blake Richards, chief executive officer, Elucid. “A true thought leader, his expertise executing vision and growing organizations will help propel Elucid as we grow commercially and realize the next phase of our mission to provide comprehensive and accurate clinical insights that enable unprecedented precision healthcare for vascular disease.”Miller is a health technology veteran with an acumen for transforming startups and growth-stage companies into mature organizations

BOSTON--(BUSINESS WIRE)--Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Scott Burger as chief commercial officer. His appointment comes as Elucid expands the commercial footprint of its PlaqueIQ technology, the only FDA-cleared plaque analysis software to identify and match CT images to patient tissue samples, simulating what a pathologist would see under a microscope.“We welcome Scott to our senior leadership team at this important time of growth for the company. His vast range of leadership experiences in the medical device and services space is exactly what we are looking for to take us to the next level as we increase our commercial footprint,” said Blake Richards, chief executive officer, Elucid. “Scott’s knowledge and track record of success will be vital for Elucid as we launch several next generation plaque and FFR CT products in the coming months.”Scott brings more than 15 years of leadership experience and will lead sales, marketing, market access and customer success. He joins Elucid from CorVista Health, a non-invasive cardiac diagnostics company that combines advanced disciplines of mathematics, physics and machine-learning to reshape existing care pathways. Prior to his tenure at CorVista, Scott was commercial vice president at HeartFlow, and previously held leadership roles at Johnson & Johnson, superDimension, Bard and ConvaTec.“Being at the forefront of what’s next in cardiovascular care is my passion, and I am thrilled to join Elucid at this exciting time of growth,” said Burger